A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)

Trial Profile

A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Selinexor (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 29 May 2017 Planned End Date changed from 27 Sep 2020 to 16 Nov 2020.
    • 29 May 2017 Planned primary completion date changed from 27 Mar 2020 to 16 May 2020.
    • 29 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top